ReviewBlood advances2018
Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?
Review in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma.Current oncology (Toronto, Ont.) · 2025Article
- Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances.International journal of molecular sciences · 2023Review
- Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches.Experimental hematology & oncology · 2022Review
- Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.Journal of personalized medicine · 2022Review
- The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma.Clinical hematology international · 2021Article
- Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment.Bone marrow transplantation · 2020Article
- Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.Therapeutic advances in hematology · 2020Review
- Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.Blood advances · 2019Article
- Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.Blood advances · 2018Article
- Allogeneic stem cell transplant in relapsed/ refractory Hodgkin lymphoma: A 21 years' experience.Porto biomedical journalArticle
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.